Mabion S.A. (WSE: MAB) is a Polish biopharmaceutical company founded in 2007, which is undergoing a transformation into a fully integrated contract development and manufacturing organisation (CDMO) providing a broad spectrum of services in the segment of small and medium-sized projects at various stages of development (from early stage discovery to commercial manufacturing). Mabion's competencies include the selection of protein expression technologies, their purification, GMP-standard manufacturing activities (obtaining Active Substances "Drug Substance" and Finished Products "Drug Product"), the development of analytical tools (for structural, functional, physicochemical characterisation), clinical development, clinical analytics and a full range of regulatory activities in the development and operational areas. The company signed a record contract with Novavax in October 2021 for the commercial production of antigen for the COVID-19 vaccine, which it has since steadily expanded through further services under the Statement of Work (SOW) and annexes signed, adding, among other things, another vaccine product based on the Omicron variant. In line with the Strategy announced in April 2023, the Company's objective is to establish itself as a recognisable player in the global contract manufacturing and contract drug development market and to complete the full transformation of Mabion into an integrated biologics CDMO company. Mabion is a public Company, listed on the Warsaw Stock Exchange. For more information about the Company, visit www.mabion.eu.
View Top Employees from Mabion S.A.Website | http://www.mabion.eu |
Ticker | MAB |
Revenue | $9 million |
Employees | 181 (136 on RocketReach) |
Founded | 2007 |
Address | 9 Ul. Józefow, Kutno, Lodz Voivodeship 99-300, PL |
Phone | +48 42 290 82 10 |
Fax | +48 42 355 17 77 |
Technologies |
JavaScript,
HTML,
Google Analytics
+14 more
(view full list)
|
Industry | Pharmaceutical Manufacturing, Manufacturing General, Biotechnology, Manufacturing, Science and Engineering, Pharmaceutical, Health Care |
Keywords | Drug Development And Manufacturing, Biopharmaceuticals, Clinical Analytics |
Competitors | ActivX Biosciences, Affectis Pharmaceuticals, Formycon AG, Olema Pharmaceuticals, Inc., Zentaris GmbH |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies |
Looking for a particular Mabion S.A. employee's phone or email?
The Mabion S.A. annual revenue was $9 million in 2024.
136 people are employed at Mabion S.A..
Mabion S.A. is based in Kutno, Lodz Voivodeship.
The NAICS codes for Mabion S.A. are [32541, 3254, 325, 32].
The SIC codes for Mabion S.A. are [283, 28].